FC:AI · OPEN SOURCE ME · CANCER PROFILE
Russ Read-Barrow
Bath, UK · Treated at The Bath Clinic, Claverton Down, Bath
No known drug allergies · WHO performance status 0
No known drug allergies · WHO performance status 0
CORRECT AS AT
30 SEPTEMBER 2026
Check the QR code for the latest version
30 SEPTEMBER 2026
Check the QR code for the latest version
Stage
IV
Metastatic
CEA
44.6
ug/L · 29 Sep 26 · ref 0–5.2
Cycle
4
of this block · 16th FOLFIRI+cetux overall
WHO PS
0
Fully active · 24 Aug 26
PD-L1
<1%
TPS · negative
Diagnosis
Moderately differentiated adenocarcinoma, rectosigmoid colon
ypT4a ypN1b (3/24 nodes) M1a V+ · Treatment began Dec 2021; primary resected Mar 2022
Where it is now: Lungs · mediastinal lymph nodes · liver segment VII (new, Jul 2026)
- Smouldering myeloma (diagnosed end of 2021, under haematology surveillance)
- Gilbert's syndrome (can raise bilirubin)
Molecular profile EXACTA report, 1 Sep 2025
KRAS/NRAS wild-typeBRAF wild-typepMMR / MSSHER2 IHC 0TMB-low · 3 Mut/MbPD-L1 <1% (22C3, 28-8)PTEN no variant detectedAPC
p.S1415Rfs*4PathogenicFrameshift · tissue MAF 8.5% · cfDNA 0.62%
TP53
p.R342*PathogenicNonsense · tissue MAF 9.21%
VUS: RUNX1T1, FANCM, CIC, BCR, CYP2D6. Exploratory (Astron/ICC): MTOR and VEGFR1/2 protein positivity, HMGB1 overexpression
Current treatment 14 days cycles
FOLFIRI + cetuximab (rechallenge, 3rd block)
C119 Aug 26
C22 Sep 26
C316 Sep 26
C430 Sep 26
C514 Oct 26
C6TBC
Cetuximab500 mg/m²1000 mg
Irinotecan180 mg/m²400 mg
5-FU bolus400 mg/m²900 mg
5-FU infusion (46h)2400 mg/m²5000 mg
Folinic acid350 mg
Full doses, dose-banded · BSA 2.08 m² (84.5 kg, 185 cm, 16 Sep 26)
Plan: 8–12 weeks, then consider maintenance 5-FU + cetuximab if response is good. CT after Cycle 5.
CEA tumour marker ug/L
FOLFIRI + cetuximab blocks · 19 readings, Apr 2025 – Sep 2026
Key bloods 29 September 2026
Haemoglobin126 g/L LOW130–170
Red cells4.09 ×10¹²/L LOW4.40–5.80
White cells9.69 ×10⁹/L3.0–10.0
Neutrophils7.15 ×10⁹/L2.0–7.5
Lymphocytes1.67 ×10⁹/L1.2–3.65
ALT23 U/L10–50
AST26 U/L10–50
ALP169 U/L HIGH30–130
Bilirubin21 µmol/L HIGH0–20
Albumin42 g/L35–50
Globulin33 g/L19–35
Creatinine76 µmol/L59–104
eGFR>90 mL/min/1.73m²
Magnesium0.80 mmol/L0.7–1.0
Potassium4.0 mmol/L3.5–5.3
Adjusted calcium2.43 mmol/L2.2–2.6
Latest imaging
23 Jul 2026 · CT chest, abdomen & pelvis
Progression above and below the diaphragm, and a new liver metastasis
CT report, 23 Jul 2026, compared with May 2026
Before that: 12 May 2026, CT chest, abdomen & pelvis: “Good response to treatment within the mediastinum and lungs.”
Treatment history
- Dec 21–Feb 22Neoadjuvant XELOX ×4 · good partial response
- Mar–Oct 22Primary resected · liver met resected (R0) · adjuvant CAPOX
- Oct 22–Apr 23Lung mets appear, progress · SABR 55 Gy/5
- Jun & Aug 24Lung ablations (1 left, then 1 left + 4 right)
- Feb 25EBUS confirms mediastinal nodal disease
- Apr–Jul 25FOLFIRI + cetuximab ×6 · good partial response
- Feb–May 26Rechallenge ×6 · good response (CT 12 May)
- Jul–Aug 26Progression during the break · FOLFIRI + cetuximab restarted 19 Aug
Medication & protocol Current meds · 17 Sep
Chemo dayStandard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after
SupportiveDexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN
OtherCitalopram 30 mg (breakfast) · melatonin 60 mg (evening) · metformin MR 500 mg (new, 30 Sep) · loratadine 10 mg
PausedMistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice
What I'm looking into
- BNT314 + pumitamig (BNT327) + chemo · MSS/pMMR mCRC
- Botensilimab + balstilimab · pre-treated MSS CRC
- WNT/β-catenin-targeted: ST316 (NCT05848739, phase 1–2) · tegavivint
Know this profile? Patients with similar disease, oncologists, scientists and geneticists — I want to hear from you. Not generic advice, please.